---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-005535"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:22:47.243705+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics appoints Scott Garland to board; Phillips resigns as ELVN prepares for Phase 3

## Summary
- Scott Garland appointed as Class I director and Chair of Nominating and Corporate Governance Committee effective Jan 7, 2026.
- Garland receives $40k annual cash (director) + $10k (committee chair) and initial stock option grant with ~$650k fair value vesting over 3 years.
- Andrew Phillips resigned from board and committees effective Jan 7, 2026; resignation not due to any disagreement with company.
- Garland brings biopharma commercial expertise as company advances ELVN-001 toward Phase 3 pivotal trial in CML in 2026.

## SEC filing metadata
- accession: 0001193125-26-005535
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312526005535/0001193125-26-005535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312526005535/d28332d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-005535
- JSON: https://secwatch.observer/filing/0001193125-26-005535.json
- Plain text: https://secwatch.observer/filing/0001193125-26-005535.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.